Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.45 |
| ▸ | CETP | P11597 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19827331 | 1.00 | MEN1 (0.53) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL15281661 | 1.00 | MEN1 (0.53) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL15281660 | 0.98 | MEN1 (0.50) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL16588596 | 0.92 | MEN1 (0.42) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL17035837 | 0.89 | CNR2 (0.50) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL16588609 | 0.89 | MEN1 (0.43) | MEN1KMT2ADEGS1PRSS1CTSG | |
| SCHEMBL21914995 | 0.87 | MEN1 (0.53) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL19827423 | 0.86 | PRSS1 (0.42) | MEN1KMT2ADEGS1FAAHASAH1 | |
| SCHEMBL21914999 | 0.86 | MEN1 (0.49) | MEN1KMT2ADEGS1CETPTHRB | |
| SCHEMBL19827418 | 0.86 | MEN1 (0.51) | MEN1KMT2ADEGS1CETPTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551959-B2 | Glycolipid and use thereof | RIKEN (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | SGMS1, UGCG, SGPL1 | MEN1 1021/4885KMT2A 2903/4885DEGS1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.